Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Curis, Inc.
Mayo Clinic
Pfizer
Memorial Sloan Kettering Cancer Center
Miltenyi Biomedicine GmbH
Incyte Corporation
M.D. Anderson Cancer Center
Amgen
National Institutes of Health Clinical Center (CC)
Institute of Hematology & Blood Diseases Hospital, China
Dren Bio
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
BeOne Medicines
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Instituto de Investigación Biomédica de Salamanca
M.D. Anderson Cancer Center
AstraZeneca
BeOne Medicines
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Texas Southwestern Medical Center
Novartis
BeOne Medicines
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Kelonia Therapeutics, Inc.
University of Washington
National Institutes of Health Clinical Center (CC)
Institute of Hematology & Blood Diseases Hospital, China
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
National Cancer Institute (NCI)
AVM Biotechnology Inc
New York Medical College
New York Medical College